Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
11/2005
11/22/2005US6967106 Purification; removal by-products; side effect reduction
11/22/2005US6967088 Soluble recombinant botulinum toxin proteins
11/22/2005US6967076 A reporter sequence consists of a reporter gene whose expression is regulated by a protein specific to HIV viruses, expressed from a genome of an HIV virus upon infection of a cell tranduced by genetic engineered viral vector
11/22/2005US6967022 Ganglioside-KLH conjugate vaccines plus QS-21
11/22/2005CA2267639C Synthetic hpv16 virus-like particles
11/22/2005CA2171531C Multiple branch peptide constructions for use against hiv
11/22/2005CA2068066C Herpesvirus particles and vaccine
11/17/2005WO2005108996A1 Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 10 (dpp10)
11/17/2005WO2005108584A1 Recombinant chemokine-antigen vaccine
11/17/2005WO2005108580A1 Mutant pneumolysin proteins
11/17/2005WO2005108575A1 T-type calcium channel splice variant compositions and methods
11/17/2005WO2005108431A1 Methods and compositions for the treatment of ocular neovascularization
11/17/2005WO2005108428A2 Cd40 splice variants and their uses
11/17/2005WO2005108420A1 Cancer associated antigens
11/17/2005WO2005108419A1 Mutant cholesterol-binding cytolysin proteins
11/17/2005WO2005107803A2 Methods of determining the prognosis and treatment of subjects with lung cancer
11/17/2005WO2005107802A2 Method and system to remove soluble tnfr1, tnfr2, and il2 in patients
11/17/2005WO2005107801A2 Systems and methods for treating human inflammatory and proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors and/or ucp and/or fas antibodies
11/17/2005WO2005107800A1 Monoclonal antibodies to hepatocyte growth factor
11/17/2005WO2005107799A1 REMEDY FOR CANCER CONTAINING ANTI-Necl-5 ANTIBODY AS THE ACTIVE INGREDIENT
11/17/2005WO2005107798A1 NEISSERIA MENINGITIDIS IgtB LOS AS ADJUVANT
11/17/2005WO2005107797A1 Influenza virus vaccines
11/17/2005WO2005107796A2 Cellular permissivity factor for viruses, and uses thereof
11/17/2005WO2005107793A2 Ngal for reduction and amelioration of ischemic and nephrotoxic injuries
11/17/2005WO2005107785A2 Human complement c3 derivates with cobra venom factor-like function
11/17/2005WO2005107784A1 Remedy for thrombopenia
11/17/2005WO2005107767A2 Modulation of lysophosphatidylcholine and treatment of diet-induced conditions
11/17/2005WO2005107381A2 Use of flagellin as an adjuvant for vaccine
11/17/2005WO2005083385A3 Method of evaluating the therapeutic potential of a vaccine for mucosal administration
11/17/2005WO2005071088A3 Recombinant nucleic acid molecules encoding fusion proteins comprising antigens and bacterial secretory signal polypeptides, expression cassettes, and bacteria, and methods of use thereof
11/17/2005WO2005058356A3 Methods for porducing storage stable viruses and immunogenic compositions thereof
11/17/2005WO2005058251A3 Hla-dr-specific antibodies, compositions and methods
11/17/2005WO2005050203A3 The methods for screening using ctgf and trka receptor for the identification of compounds for use in treatment of fibrosis
11/17/2005WO2005049802A3 Anti-hydroxylase antibodies and uses thereof
11/17/2005WO2005047309A3 Prophylactic and therapeutic monoclonal antibodies
11/17/2005WO2005046622A3 Custom vectors for treating and preventing pancreatic cancer
11/17/2005WO2005030122A3 Inactivated host cell delivery of polynucleotides encoding immunogens
11/17/2005WO2005020972A3 Combination therapy for the treatment of ocular neovascular disorders
11/17/2005WO2005014629A3 Protein from photobacterium damselae and use thereof
11/17/2005WO2005009397A3 Human lymphocyte vaccine adjuvant
11/17/2005WO2004073736A8 Attenuated strains of vibrio cholerae and lyophilised vaccines containing same
11/17/2005WO2004071422A3 Streptococcal serum opacity factors and fibronectin-binding proteins and peptides thereof for the treatment and detection of streptococcal infection
11/17/2005WO2001065911A9 Improved poloxamer and poloxamine compositions for nucleic acid delivery
11/17/2005US20050256304 Modified factor VIII
11/17/2005US20050256299 Vaccines
11/17/2005US20050256073 Immunostimulatory viral RNA oligonucleotides
11/17/2005US20050256070 Adjuvant
11/17/2005US20050256067 Method of preparing a treatment product, treatment product and a plasmid construct
11/17/2005US20050256060 Mono-and disaccharide derivatives
11/17/2005US20050256054 Drug therapy for celiac sprue
11/17/2005US20050256050 Vascular endothelial growth factor 2
11/17/2005US20050256049 Chimeric toxins for targeted therapy
11/17/2005US20050256043 chemokines; open reading frames; long terminal repeats; site directed mutagenesis; antibodies
11/17/2005US20050255561 Conjugate comprising peptides based on extracellular loop of P glycoprotein attached to spacer molecules with phospholipid and amino acid attached to opposite temini; synthesis; hybridoma, monoclonal antibodies; kits
11/17/2005US20050255555 Monoclonal antibody specific to epidermal growth factor receptor for targeting tumors and treating cancer; tissue targeted therapy
11/17/2005US20050255529 Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor
11/17/2005US20050255518 Methods and compositions for the treatment and diagnosis of pain disorders using 46566
11/17/2005US20050255454 Administering antigens capable of causing specific immune reaction(s) directed against an infectious agent and/or cells infected with the infectious agent, and decreasing a different specific immune reaction direct towards the infectious agent, infected cells and/or uninfected cells; immunotherapy
11/17/2005US20050255162 Hydrophobic biomolecular structure
11/17/2005US20050255138 Active agent transport systems
11/17/2005US20050255129 Treatments and methods for treatment, diagnosis and prophylaxis
11/17/2005US20050255127 Recombinant vaccine against West Nile Virus
11/17/2005US20050255125 Streptococcus uberis protein, nucleic acid sequence encoding the same and its use in a mastitis vaccine
11/17/2005US20050255124 HCV E1E2 vaccine compositions
11/17/2005US20050255123 Chimeric ebola virus envelopes and uses therefor
11/17/2005US20050255122 particularly, preventing or ameliorating the neuropathology of Alzheimer's disease, by administering an A beta peptide having a specific amino acid sequence and an adjuvant that enhances the immune response
11/17/2005US20050255121 An immunogenic or antigenic agent and a gelling agent and mucoadhesive or bioadhesive such as carboxymethyl cellulose for intradermal delivery; enhanced efficacy allows lower doses of antigenic or immunogenic agent than conventionally used, and without the need for booster immunizations
11/17/2005US20050255120 Composition and method for introduction of DNA directed RNA interference sequences into targeted cells and tissues
11/17/2005US20050255119 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
11/17/2005US20050255118 Methods and composition for treating tumors and metastatic disease
11/17/2005US20050255117 Administering an antibody to specifically bind an epitope in the cysteine-rich domain of Cripto protein; binding to an epitope in the ligand/receptor binding domain of either a native or denatured form; binding to an epidermal growth factor-like domain; angiogenesis inhibitors; antitumor agents
11/17/2005US20050255116 Combination of tumor-associated surface protein antigens and tumor-associated sugars in the treatment and diagnosis of cancer
11/17/2005US20050255115 T-cell surface glycoprotein specific immunoglobulin for use in treatment and prevention of cell proliferative disorders; immunotherapy
11/17/2005US20050255114 Methods and diagnosis for the treatment of preeclampsia
11/17/2005US20050255113 Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders
11/17/2005US20050255112 Compositions and methods for preventing erythropoietin-associated hypertension
11/17/2005US20050255111 Use of an inhibitor or antagonist against tissue factor
11/17/2005US20050255110 Method for ex vivo immunization using heterologous intact bispecific and/or trispecific antibodies
11/17/2005US20050255109 Methods and compositions for inhibition of metastasis
11/17/2005US20050255108 For improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size in absence of removal of the arterial obstruction; administering anti-CD18 antibody
11/17/2005US20050255107 Anti-angiogenic proteins and fragments and methods of use thereof
11/17/2005US20050255106 Induction of anti-tumor ctl immunity through in vivo triggering of 4-1bb and/or cd40
11/17/2005US20050255105 Severe myelin deficits induced by self-reactive gamma delta T cells
11/17/2005US20050255104 administering antibodies or antigen-binding fragments which are specific for human tumor necrosis factor- alpha (TNF alpha), used for in vivo medical diagnosis and therapy; immunoassay and immunotherapy
11/17/2005US20050255102 binds to alpha v beta 6 and not other alpha v integrins or non-specific integrins; inhibits the binding of alpha v beta 6 to latency associated peptide with an IC50 value lower than that of 10D5 and binds alpha v beta 6 in manner that does not distinguish between the use of Ca2+/Mg2+ and Mn2+ for cation
11/17/2005US20050255101 Antibody having a t-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
11/17/2005US20050255100 Isolated nucleic acid encoding a human polypeptide, tumor necrosis factor receptor-5; tumor necrosis factor blocking agent; cyclosporine immunosuppressant; antibiotic; anti-inflammatory; graft versus host disease, viral infection, cancer, leukemia, immunodeficiency, autoimmune disorder
11/17/2005US20050255099 Antigenic fusion protein carrying Galalpha 1,3Gal epitopes
11/17/2005US20050255098 Methods of treating traumatic spinal cord injury
11/17/2005US20050255088 Administering mutant Salmonella sp. for therapy of solid tumor cancer, disrupted msbB gene and is capable of targeting a solid tumor cancer
11/17/2005US20050255085 Prevention of recurrence and metastasis of cancer
11/17/2005US20050255083 Multimeric protein toxins to target cells having multiple identifying characteristics
11/17/2005US20050255041 Administering monoclonal antibody or antigen binding fragment accession number 270404-01; primary and metastatic tumors
11/17/2005US20050255039 Gel injection treatment of breast, fibroids & endometrial ablation
11/17/2005CA2566344A1 Mutant pneumolysin proteins
11/17/2005CA2566041A1 T-type calcium channel splice variant compositions and methods
11/17/2005CA2565701A1 Ngal for reduction and amelioration of ischemic and nephrotoxic injuries
11/17/2005CA2565387A1 Modulation of lysophosphatidylcholine and treatment of diet-induced conditions
11/17/2005CA2565227A1 Human complement c3 derivates with cobra venom factor-like function
11/17/2005CA2565215A1 Method and system to remove soluble tnfr1, tnfr2, and il2 in patients
1 ... 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 ... 1823